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Background: Increasing the scope of an evidence based approach to areas outside healthcare has renewed the
importance of a long-standing discussion on randomised versus observational study designs in evaluating the
effectiveness of interventions. We investigate statistically if an increasing recognition of the role of certain
nonrandomised studies to support or generalize the results of randomised controlled trials has had an impact on
the actual inclusion criteria applied in Cochrane reviews.
Methods: We conduct an on-line search of the Cochrane Database of Systematic Reviews (CDSR) and divide all
Cochrane reviews according to their design inclusion criterion: (A) RCTs only or (B) RCTs and (some subset of)
observational studies. We test statistically whether a shift in the proportion of category B reviews has occurred by
comparing reviews published before 2008 with reviews published during 2008/09.
Results: We find that the proportion of Cochrane reviews choosing a broader inclusion criterion has increased,
although by less than two percentage points. The shift is not statistically significant (P = 0.08).
Conclusions: There is currently not sufficient data to support a hypothesis of a significant shift in favour of
including observational studies, neither at the aggregate level nor at the level of individual Review Groups within
the Cochrane Collaboration.
Keywords: Systematic reviews, Observational study, Randomized controlled trialBackground
“Evidence based medicine is the conscientious, explicit,
and judicious use of current best evidence in making
decisions about the care of individual patients” [1]. This
is the oft-cited definition of evidence based medicine
(EBM) [2]. As one of the most visible parts of the EBM
movement, the Cochrane Collaboration [3] was estab-
lished in 1993 as an international not-for-profit inde-
pendent organization. It has produced around 4,000
systematic reviews of the effects of healthcare interven-
tions. More recently, there have been efforts to extend
the evidence based approach to policy areas outside
healthcare. The Campbell Collaboration [4,5] was set up
in 2000 to facilitate systematic reviews of the effects of
social interventions in areas such as social work, educa-
tion and crime & justice. (Its close cooperation with the* Correspondence: Kongsted@econ.ku.dk
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October 2010 joint colloquium [6]).
This expansion of scope of the evidence-based approach
has renewed the long-standing discussion of the role of
randomised versus observational study designs [7-27]. A
key feature of EBM is advocating a hierarchy of what con-
stitutes “current best evidence” on effectiveness. Evidence
from systematic reviews of several high-quality rando-
mised controlled trials (RCTs) rank at the top, followed by
single RCTs, and then observational studies [28]. Rando-
mised studies are thus widely regarded as a priori most
likely to produce an unbiased estimate of effect [24]. There
is, however, an increasing recognition of the role of non-
randomised studies, either to support the results of RCTs,
or in cases where there are no existing RCTs [24]. This
role is likely to be much emphasized when assessing the
effectiveness of non-healthcare public policies due to the
relative shortage of RCTs in such areas.
Despite this focus on primary study design, there appears
to be little if any quantitative information on how the actualed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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interventions have evolved over time. By producing such
evidence based on the existing reviews of the Cochrane
Database of Systematic Reviews (CDSR), our primary aim is
to inform the discussion of the roles of randomised and
nonrandomised studies for an evidence-based approach in
fields outside healthcare. Due to similarity of the setups of
the Cochrane and Campbell Collaborations [5], we argue
that analysing the former is informative for the discussion
on how to implement systematic reviewing of social inter-
ventions within the latter. It is known that the Cochrane
Collaboration has a stronger focus on RCTs when com-
pared to systematic reviews produced by others in the med-
ical literature [29,30]. Still, the analysis of the CDSR is
arguably of interest in itself. It has risen to the top-10 in the
Thomson ISI “MEDICINE, GENERAL & INTERNAL” cat-
egory [3] in terms of its impact factor and it is thus an in-
creasingly influential source of information within the
medical literature.
Specifically, we examine how the criteria for inclusion
of different primary study designs have varied both over
time and across different medical fields. The fundamen-
tal distinction that we focus on is between experimental
and observational designs [24]. As most of the existing
literature, we will use the terms observational and non-
randomised interchangeably.
The production of Cochrane reviews and the subse-
quent editorial review process is guided (but not ruled) by
the Cochrane Handbook [31]. The overarching principle
of the current Handbook (section 5.5) is that “[r]andomi-
sation is the only way to prevent systematic differences be-
tween baseline characteristics of participants in different
intervention groups in terms of both known and unknown
(or unmeasured) confounders. . .” [31]. Still, in accordance
with this principle, the Handbook (section 13.1.2) allows
the inclusion of non-randomised studies “a) [t]o examine
the case for undertaking a randomised trial by providing
an explicit evaluation of the weaknesses of available [non-
randomised studies] . . . b) [t]o provide evidence of the
effects (benefit or harm) of interventions that cannot be
randomised, or which are extremely unlikely to be studied
in randomised trials . . . c)[or to] provide evidence of effects
(benefit or harm) that cannot be adequately studied in
randomised trials, such as long-term and rare outcomes, or
outcomes that were not known to be important when exist-
ing, major randomised trials were conducted” [31].
In analyzing if there are changes in the actual inclusion
criteria applied in Cochrane reviews, we pay special atten-
tion to the time of publication of version 5 of the
Cochrane Handbook [31] in September 2007. It devotes a
full chapter to the role and quality of observational stud-
ies. Previous versions of the Handbook (up to and includ-
ing version 4.2.6) relegated the discussion to a short
appendix. While we focus on end-2007, the exact cut-offpoint in time should not be seen as a main issue. We con-
duct sensitivity analyses for alternative dates of a potential
shift and investigate more generally if there was a shift in
research design inclusion criteria of Cochrane reviews
published towards the end of the recent decade.
The above list of cases in which non-randomised study
designs can be included, could apply more often in some
medical subfields than in others. We therefore also in-
vestigate the set of reviews that originates from each of
the so-called Cochrane Review Groups (CRGs) set up in
the Cochrane Collaboration to manage the editorial
process within a specific medical subfield.
Methods
Data sources and definitions
We conducted an on-line search of the Cochrane Data-
base of Systematic Reviews (CDSR), issue 3, 2009. We split
the total pool of Cochrane reviews into two mutually ex-
clusive and exhaustive categories according to their choice
of which research designs to include: (A) RCTs only or (B)
RCTs and (some subset of) observational studies. We
identified category (B) reviews among those generated by
the search string “non NEXT random* OR nonrandom*
OR non NEXT rct” applied to the full text of the review.
The Cochrane Handbook uses the term “non-random”
when discussing observational studies. Our search string
thus identifies the reviews that explicitly consider whether
or not to include such studies.
The identified reviews constitute a gross measure of
category (B) reviews in the sense that some reviews sim-
ply mention observational studies but decide not to in-
clude them. We therefore manually analyzed each
review within the gross selection and identified those
reviews that actually allowed for the inclusion of (some
subset of) observational studies. The manual analysis
was based on the subsection “Types of Studies” in the
Methods section of the standardized lay-out for
Cochrane reviews. We checked inter-coder reliability by
having the two authors independently assign categories
to 1 review randomly selected in every 25 reviews within
the gross selection. There was agreement on the proper
categorization of all randomly sampled reviews. As a fur-
ther check for possible misclassification, we also applied
our manual search to the first 25 reviews listed when we
simply sorted all Cochrane reviews alphabetically by
title. Eight of these were already in our selection. One
had been withdrawn. Of the remaining 16 reviews, all
included only RCTs or quasi-RCTs, none allowed for the
inclusion of observational studies. This validates our
gross selection criteria.
Statistical analysis
We analyze the full period of the CDSR as well as two
sub-periods – before or after January 1st, 2008 – as
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The editorial process of reviews published before January
1st, 2008, was fully or predominantly guided by the
Handbook version 4.2.6 (or earlier versions). For reviews
published after January 1st, 2008, version 5 of the Hand-
book [31] from September 2007 has definitely been avail-
able during long stretches of the review production
process. We use likelihood ratio χ2 tests throughout. A
P-value of less than 0.05 was considered to indicate stat-
istical significance.Sensitivity analyses
We subdivided category (A) into an (A1) category of
reviews that use a strict RCT-only inclusion criterion
and an (A2) category of reviews that additionally allow
for the inclusion of quasi-randomised trials. The
Cochrane Handbook [31] (section 13.1.1) uses the term
quasi-randomised trial to signify “inappropriate random-
isation strategies” (e.g. alternate or case file number)
where bias is potentially introduced through
unrecognized correlation between the sequence gener-
ation mechanism and the outcome(s) of interest. While
quasi-randomised studies cannot be considered as a
proxy for observational studies, they are a “grey zone” in
terms of proper randomisation. For the main analysis,
we grouped categories (A1) and (A2) together. We per-
form a sensitivity analysis by eliminating category (A2)
from the analysis altogether.
In order to increase the power of our analysis against
changes that took place gradually, we also present a sen-
sitivity analysis that compares 2008/09 reviews to the
reviews that were published prior to 2006.Results and discussion
Table 1 illustrates how the total pool of Cochrane reviews is
distributed according to study design inclusion criteria. The
reviews are divided into three categories: (A1) Reviews that
only allow for RCTs; (A2) for RCTs and quasi-randomised
designs; or (B) for RCTs, quasi-randomised designs and
(some subset of) observational study designs. The table alsoTable 1 Distribution of Cochrane reviews over inclusion criter
Study design inclusion criteria
(A1) Randomised controlled trials
(A2) Randomised controlled trials and quasi-randomised trials
(B) Randomised controlled trials, quasi-randomised trials, and (some subset o
observational studies
Total
Source: Cochrane Database of Systematic Reviews, Issue 3, 2009. A list of the categoprovides separate distributions for reviews published prior
to 2008 or during 2008/09.
The vast majority of existing Cochrane reviews – 87 per
cent – belong to category (A1). They only allow for the in-
clusion of RCTs. Category (A2) reviews which in addition
include quasi-randomised designs, add another seven per-
centage points. Approximately six per cent of all Cochrane
reviews are category (B) reviews that allow for the inclu-
sion of (some subset of) observational study designs.
Figure 1 illustrates the evolution of this distribution
since the mid 1990ies. An eye-ball inspection seems to
suggest that the proportion of category (B) reviews is
trending upwards although quite slowly. The early part
of the figure is based on very few reviews – hence the
large variance.
Comparing the reviews published pre-2008 to reviews
published in 2008/09 (Table 1), we find that the category
(B) proportion has increased by less than two percentage
points. The change is not statistically significant (P =
0.08). Likewise, a statistically insignificant result (P =
0.07) is obtained when we eliminate “grey zone” category
(A2) reviews from the analysis. Consequently, there is
currently not sufficient data at the aggregate level to sta-
tistically reject that the proportion of Cochrane reviews
which include (some subset of) observational studies has
remained constant.
Despite the insignificant finding at the aggregate level,
there is still a possibility of diverging trends within dif-
ferent medical subfields. To investigate this, Figure 2
orders the CRGs horizontally by increasing pre-2008
proportion of category (B) reviews. (A similar picture
emerges when eliminating the “grey zone” category (A2)
reviews.) Individual subfields are seen to range widely
from a low of zero category (B) reviews in the “Haem-
atological Cancer Group” and the “Hypertension Group”
to a high of 22 per cent in the “Gynaecological Cancer
Group”. The variation across fields confirms the hypoth-
esis that the supplementary role of observational studies
differs greatly between fields.
Figure 2 makes it possible to do an eye-ball inspection
of the possible presence of a structural shift at the levelia








3,398 (87.2) 2,563 (87.9) 835 (85.2)
277 (7.1) 199 (6.8) 78 (8.0)
f) 222 (5.7) 155 (5.3) 67 (6.8)
3,897 (100.0) 2,917 (100.0) 980 (100.0)
ries assigned to individual reviews is found in the Additional file 1.
Figure 1 Distribution of Cochrane reviews across inclusion
criteria.
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difference between the actual number of category (B)
reviews published in 2008/09, and the number to be
expected had the pre-2008 proportions remained un-
changed. Values larger (smaller) than zero indicate that
the proportion of category (B) reviews in a CRG
increased (decreased).
The differences between actual and expected changes
are seen to be fairly equally divided between increases
(21 CRGs) and decreases (28 CRGs). (The “Childhood
Cancer Group” had no pre-2008 reviews and is therefore
not included.) The graphical interpretation of Figure 2






















Figure 2 Production of observational-inclusive (category B)
reviews by Review Groups in the Cochrane Collaboration. Note
for Figure 2: Vertical axis: Actual number of category (B) reviews
published in 2008/09 minus the number to be expected given pre-
2008 proportions. Horizontal axis: Pre-2008 proportion of category
(B) reviews. Example: a negative number means that a review group
has produced fewer category (B) reviews in 2008 or 2009 than
would be expected from its production prior to 2008.proportion has limited “downside” within previously
low-proportion CRGs. Among the ten CRGs having the
highest pre-2008 proportion of category (B) reviews,
eight show a declining proportion (Figure 2). Increases
are found only in two of the top-ten CRGs: The “Effect-
ive Practice and Organisation Group” and the “Injuries
Group”. Both groups focus on behavior modifying inter-
ventions rather than RCT-intense pharmacological
interventions.
Formal testing of significance within subfields requires
a sufficiently large number of reviews to be expected in
2008/09 (given unchanged pre-2008 proportions). This
can be achieved by a large review production in general,
a high pre-2008 proportion of category (B) reviews, or
both. None of the individual CRGs currently qualify for
testing under a standard requirement of at least five
expected observations.
The strict comparison of pre- and post-2008 reviews
could potentially miss a shift that happened gradually.
First, a number of reviews published in 2008/09 had
their protocol formally approved under the guidance of
Handbook version 4.2.6. The protocol includes the
very study design criterion on which we base our
categorization of reviews. Cochrane reviews are
approved sequentially (title, protocol, review) and typic-
ally over several years. Statistically correcting for this po-
tential source of bias must await the publication of more
reviews governed by Handbook version 5 “from start to
finish”. Secondly, any change within an individual CRG
could have predated the publication of Cochrane Hand-
book version 5. Given that the Handbook is a guide, not
a rule book, a change in the rate of inclusion of observa-
tional studies could have been present in actual review
practice already during years prior to the actual publica-
tion date of Handbook version 5.
As a sensitivity analysis, we therefore introduced a
two-year separation between the sub periods, comparing
980 2008/09 reviews and 1,755 reviews published prior
to 2006. A very similar picture emerged from this ana-
lysis: The aggregate proportion of category (B) reviews
does increase but still not significantly; 20 CRGs show
increasing category (B) proportions, 29 show decreases;
and there is not enough data to allow formal significance
testing at the level of the individual CRGs.
Conclusions
The methodological debate on the role of observational
studies in formalized research synthesis has been on-
going in medical research. The present analysis docu-
ments how the formal guidelines of the Cochrane
Collaboration have impacted on actual review practice.
The main conclusions are threefold.
First, the overall distribution of Cochrane reviews
according to inclusion criteria reflects a clear and
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showed a large range of variation in the rate at which
reviews allow for the inclusion of observational studies
across different medical subfields. Third, we found no
significant evidence of any subsequent shift in actual re-
view practice. This conclusion holds irrespective of
whether we use the time of publication of the Cochrane
Handbook version 5 to date the potential shift; allow for
a more gradual change by separating the sub periods by
a window of two years; or exclude reviews that allow for
quasi-randomised trials but not observational studies
from the analysis.
These conclusions have implications for extending a
similar “industrial scale” [32] review production initiative
to public policy areas outside healthcare. Even within
the realm of healthcare interventions, there is no “one
size fits all” prescription. The need for supplementing
the evidence from randomised controlled trials with sup-
porting evidence from observational studies varies
greatly across medical subfields. Most likely, this will
apply to an even greater extent for interventions outside
healthcare. Moreover, the fact that we found no signifi-
cant trends either at the aggregate level or within spe-
cific medical subfields, suggests that the rate of inclusion
of observational studies is dictated by field-specific needs
which remain fairly constant over time, rather than the
ups and downs of ongoing methodological discussions.
Additional file
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